

## Life Settlement Assets PLC – Ordinary Share E

### Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

### Commentary

The 24th Annual Spring Life Settlement Conference was held in May by LISA (Life Insurance Settlement Association) in Washington, D.C. The experts presented recent regulatory changes and technology renovations which could bring the industry to the next level, with a focus on streamlining the process of transactions such as short-form underwriting. Such advances could have the potential to not only transact a much larger number of policies before they lapse, but also to make a life settlement or viatical settlement transaction much more accessible for millions of American seniors.

The Share Class is reporting a performance of -0.40% for the month of May. One HIV maturities has been registered, contributing a total Death Benefit of \$17k. One maturity was registered in the elderly segment, for a total coverage of \$50k. Currently, maturities for the HIV segment until May almost already reaches the expected level for the whole year. However, the elderly segment underperforms due to the lack of large size policies maturing.

Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	7,628,770.05	4.4014

Number Of Policies	Death Benefits (USD)	Matured Policies YTD*	Maturities YTD (USD)*
242	23 054 457	8	239 818

**Trust Investment Manager** Acheron Capital Ltd.

**Company Secretary** Maitland Administration Services Limited


**Administrator** Compagnie Européenne de Révision

**ISIN Ticker** GB00BF1Q4D29  
LSAE

**Auditor** Grant Thornton UK LLP

**Info** life@acheroncapital.com  
+44 207 258 5990

\*This figure refers to maturities occurred in the portfolio held by Styx Portfolio Trust




(1) Indicates the available face amount to LSA which is a fractional interest of initial face amount.

(2) Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.


## Historical Maturity



## Maturities May 2018

Number of policies matured in May 2018	2
Corresponding number of insured	2
Total death benefit in May 2018 (US\$)	67 293
Valuation of Matured policies in Book (US\$)	13 652

## Notification of Maturity



## Premiums Situation (US\$) <sup>(1)</sup>

Servicers Premiums Projection as of Beginning 2018	\$ 1.5M
Mortality Adjusted Premiums Projection Beginning 2018	\$ 1.3M
Estimated COI Net of Mortality Beginning 2018	\$ 1.7M

## Top 10 Coverage

Insured	Face (million)	Total Face (millions)	Age (ALB)	Expiration Age*
1	2.2/0.3/0.3	2.8	98	101/101/101
2	1.2/0.7/0.2	2.1	98	115/100/120
3	2	2	97	100
4	0.2/0.2/0.2	0.6	75	100/121/100
5	0.6	0.6	86	95
6	0.3/0.2/0.1	0.6	90	100/100/100
7	0.5	0.5	96	100
8	0.5	0.5	69	95
9	0.4/0.03/0.02	0.4	90	95/95/95
10	0.3	0.3	77	100

## Cash Situation (US\$) <sup>(1)</sup>

Cash at hand and similar	\$ 1.0M
Gross Cash in Policies <sup>(2)</sup> (estimated as of end 2017)	\$ 821k
Loan on Cash in Policies (estimated as of end 2017)	\$ 0k
Net Cash in Policies <sup>(2)</sup> (estimated as of end 2017)	\$ 740k
Maturities to be received	\$ 1.1M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

\* In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under reference FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.